Related Experiment Video
Updated: Jan 3, 2026
07:12
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
Published on: August 2, 2021
4.0K
The Association Between Body Mass Index and Remission Rates in Patients With Treatment-Resistant Depression Who
Balwinder Singh1, William V Bobo2, Keith G Rasmussen1
1Department of Psychiatry and Psychology, Mayo Clinic Depression Center, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
The Journal of Clinical Psychiatry
|November 14, 2019
Summary
No abstract available in PubMed .
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
739
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
739
01:30Electroconvulsive Therapy
729
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
729